Pillars of growth

R&D&i

Heavy bet for R&D&i
as a future
growth engine

conocer +

R&D&i
R&D&i

Heavy bet on R&D&i
as a future
growth engine

find out more

R&D&i
Biosimilar de Enoxaparina

Biosimilars

A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.
 

find out more

Bemiparina

Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.
 

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures

+32%

2016 net profit

+9%

2016 Bemiparin sales in Spain

55 countries

International presence with 22 international partners

4 plants

for manufacturing own and third-party products in Spain

17,5 Mn€

of investment in R&D in 2016 Commitment to innovation

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors

 

Last news on Rovi 

(See all items)

0

26/07/2017

First Half 2017 Results press release

Learn about the financial results of the first half of 2017 by downloading our press release published on July 26.

0

26/07/2017

2017 first half results presentation

Operating revenues, growth data, profitability and the behavior of our products.

Last annual report

annualreport1

ROVI 2016 Annual Report

Last regular
public information

annualreport1

Financial results for the
first half of 2017